The purpose of France’s Health Data Hub (HDH) is to facilitate the sharing of health data to support research and innovation. Launched in December 2019, the HDH is a health data platform established by the French government to combine existing health databases and make them more accessible for research and development purposes [1].
The platform allows public interest project leaders to access large volumes of data and utilize the platform’s computing power to run complex research algorithms [2].
The reuse of health data has significant potential for enhancing healthcare quality and patient support through research. This includes [3]:
- Evaluating the effectiveness of treatments for rare pathologies like sarcoma by combining patient and insurance data.
- Enhancing prescription alert systems to help healthcare professionals make better decisions in complex clinical scenarios.
- Developing early warning tools for conditions like heart failure by correlating pacemaker and hospitalization data.
- Predicting disease progression, as in Parkinson’s disease, and improving preventive measures using patient cohort data.
- Streamlining the reporting and analysis of adverse drug reactions to improve healthcare system transparency.
- Utilizing AI to improve early cancer screening, thus reducing false positives and negatives, and saving medical time.
- Gathering data on long-term effects of medications, particularly in cases of organ transplantation, to optimize therapeutic strategies.
Researchers interested in accessing real-world data (RWD) and generating real-world evidence (RWE) can benefit from the HDH in several ways:
- Data Accessibility: The HDH provides a single gateway for health data in France, making it easier for researchers to access various data sources [4].
- Data Catalogue: The platform includes a data catalogue with one of the world’s largest healthcare claims databases, offering researchers a rich source of information for their studies [4].
- Collaboration: The HDH brings together 56 stakeholders, including the largest French public organization for scientific research, CNRS, fostering collaboration between government, producers of health data, and users of public and private health data [1].
- Support for Projects: The HDH provides researchers with the necessary resources and infrastructure to carry out their studies [4].
- Data Security: The platform ensures the protection of health data through a data access approval process, maintaining the privacy and security of sensitive information [4].
By providing researchers with easier access to health data and the necessary resources to analyse and process this data, the HDH can help generate valuable insights and contribute to advancements in the health sector [4].
References:
[1] Everything you need to know about Health Data Hub – Implicity
Link: https://www.implicity.com/everything-you-need-to-know-about-health-data-hub/
[2] The Health Data Hub publishes its roadmap for 2022 – French Healthcare (30 May 2022)
Link: https://frenchhealthcare.fr/the-health-data-hub-publishes-its-roadmap-for-2022/
[3] Health Data Hub – FAQ in English
Link: https://www.health-data-hub.fr/page/faq-english
[4] Health Data Hub – Multi-stakeholder workshop RWD quality and RWE use (26 June 2023)
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]







